Literature DB >> 28481851

What To Do With Lateral Nodal Disease in Low Locally Advanced Rectal Cancer? A Call for Further Reflection and Research.

Miranda Kusters1, Andrew Slater, Rebecca Muirhead, Roel Hompes, Richard J Guy, Oliver M Jones, Bruce D George, Ian Lindsey, Neil J Mortensen, Chris Cunningham.   

Abstract

BACKGROUND: There remains a lack of international consensus on the appropriate management of lateral nodal disease. Although the East manages this more aggressively with lateral lymph node dissections, the West aims to eradicate small-volume disease with neoadjuvant chemoradiotherapy and lateral nodal disease is not considered for routine surgical treatment. However, recent studies have shown that, despite neoadjuvant treatment, a significant number of patients with lateral nodal disease develop local recurrence in the lateral compartment after total mesorectal excision.
OBJECTIVE: The aim of this study is to assess the role of the pretreatment features of lateral nodes on MRI in regard to local recurrence.
DESIGN: All patients operated on for low locally advanced rectal cancer over a 5-year period were evaluated retrospectively. SETTINGS: This study was conducted at a single expert center. PATIENTS: The MRIs of a total of 313 patients were reviewed, and only those with rectal cancers up to 8 cm from the anorectal junction, measured on MRI, were selected. This left 185 patients; of these, 58 patients had clinical T1 or T2 tumors as assessed on MRI, identifying 127 patients who had cT3/T4 tumors that were included in this study. MAIN OUTCOME MEASURES: The primary outcomes measured were lateral local recurrence and multivariate analyses.
RESULTS: The lateral local recurrence rate was significantly higher (33.3% 4-year rate) in patients with nodes larger than 10 mm than in patients with smaller nodes (10.1%, p = 0.03), despite patients being irradiated in the lateral compartment. LIMITATIONS: Because this is a relatively uncommon disease, patient numbers are low, and a multicenter study is needed to further address lateral nodal disease in low rectal cancer.
CONCLUSIONS: Chemoradiotherapy with total mesorectal excision might not be sufficient in a selected group of patients. Further research is needed about which pretreatment features of the lateral nodes predict local recurrence and what is needed to prevent these from developing. See Video Abstract at http://links.lww.com/DCR/A338.

Entities:  

Mesh:

Year:  2017        PMID: 28481851     DOI: 10.1097/DCR.0000000000000834

Source DB:  PubMed          Journal:  Dis Colon Rectum        ISSN: 0012-3706            Impact factor:   4.585


  24 in total

1.  Neoadjuvant (Chemo)radiotherapy With Total Mesorectal Excision Only Is Not Sufficient to Prevent Lateral Local Recurrence in Enlarged Nodes: Results of the Multicenter Lateral Node Study of Patients With Low cT3/4 Rectal Cancer.

Authors:  Atsushi Ogura; Tsuyoshi Konishi; Chris Cunningham; Julio Garcia-Aguilar; Henrik Iversen; Shigeo Toda; In Kyu Lee; Hong Xiang Lee; Keisuke Uehara; Peter Lee; Hein Putter; Cornelis J H van de Velde; Geerard L Beets; Harm J T Rutten; Miranda Kusters
Journal:  J Clin Oncol       Date:  2018-11-07       Impact factor: 44.544

Review 2.  Cytoreduction for colorectal metastases: liver, lung, peritoneum, lymph nodes, bone, brain. When does it palliate, prolong survival, and potentially cure?

Authors:  Camille L Stewart; Susanne Warner; Kaori Ito; Mustafa Raoof; Geena X Wu; Jonathan Kessler; Jae Y Kim; Yuman Fong
Journal:  Curr Probl Surg       Date:  2018-10-04       Impact factor: 1.909

3.  Short term outcomes of minimally invasive selective lateral pelvic lymph node dissection for low rectal cancer.

Authors:  Kar Yong Wong; Aloysius Mn Tan
Journal:  World J Gastrointest Surg       Date:  2020-04-27

4.  Tumour response to neoadjuvant chemoradiation within lateral pelvic nodes: another step towards precision surgery.

Authors:  R O Perez; M D Daneri; B Vailati; G P São Julião
Journal:  Tech Coloproctol       Date:  2018-05-10       Impact factor: 3.781

5.  Utility of a three-dimensional printed pelvic model for lateral pelvic lymph node dissection.

Authors:  Daisuke Hojo; Koji Murono; Hiroaki Nozawa; Kazushige Kawai; Keisuke Hata; Toshiaki Tanaka; Soichiro Ishihara
Journal:  Int J Colorectal Dis       Date:  2020-03-02       Impact factor: 2.571

6.  Oncological Outcomes of Patients with Locally Advanced Rectal Cancer and Lateral Pelvic Lymph Node Involvement.

Authors:  Ipek Sapci; Conor P Delaney; David Liska; Sudha Amarnath; Matthew F Kalady; Scott R Steele; Emre Gorgun
Journal:  J Gastrointest Surg       Date:  2019-04-22       Impact factor: 3.452

7.  Lateral Nodal Features on Restaging Magnetic Resonance Imaging Associated With Lateral Local Recurrence in Low Rectal Cancer After Neoadjuvant Chemoradiotherapy or Radiotherapy.

Authors:  Atsushi Ogura; Tsuyoshi Konishi; Geerard L Beets; Chris Cunningham; Julio Garcia-Aguilar; Henrik Iversen; Shigeo Toda; In Kyu Lee; Hong Xiang Lee; Keisuke Uehara; Peter Lee; Hein Putter; Cornelis J H van de Velde; Harm J T Rutten; Jurriaan B Tuynman; Miranda Kusters
Journal:  JAMA Surg       Date:  2019-09-18       Impact factor: 14.766

8.  Magnetic Resonance Imaging Directed Surgical Decision Making for Lateral Pelvic Lymph Node Dissection in Rectal Cancer After Total Neoadjuvant Therapy (TNT).

Authors:  Oliver Peacock; Naveen Manisundaram; Sandra R Dibrito; Youngwan Kim; Chung-Yuan Hu; Brian K Bednarski; Tsuyoshi Konishi; Nir Stanietzky; Raghunandan Vikram; Harmeet Kaur; Melissa W Taggart; Arvind Dasari; Emma B Holliday; Y Nancy You; George J Chang
Journal:  Ann Surg       Date:  2022-07-15       Impact factor: 13.787

Review 9.  The Landmark Series: Management of Lateral Lymph Nodes in Locally Advanced Rectal Cancer.

Authors:  Oliver Peacock; George J Chang
Journal:  Ann Surg Oncol       Date:  2020-06-09       Impact factor: 5.344

10.  MRI-detected extramural vascular invasion potentiates the risk for pathological metastasis to the lateral lymph nodes in rectal cancer.

Authors:  Atsushi Hamabe; Masayuki Ishii; Koichi Onodera; Kenji Okita; Toshihiko Nishidate; Koichi Okuya; Emi Akizuki; Ryo Miura; Takahiro Korai; Masamitsu Hatakenaka; Ichiro Takemasa
Journal:  Surg Today       Date:  2021-03-04       Impact factor: 2.549

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.